Cadrenal 12-LOX inhibitor CAD-1005 shows preclinical benefits in obesity and Type 2 diabetes

Cadrenal Therapeutics, Inc.

Preclinical data: CAD-1005 improved glycemic control, reduced pancreatic β-cell loss, and lowered inflammatory cells in adipose/pancreatic tissues.
CAD-1005 also evaluated for HIT; Phase 2 trial reduced thrombotic events. Company acquired 12-LOX portfolio in Dec 2025.
Company believes CAD-1005 is the only clinical-stage 12-LOX inhibitor and may complement GLP-1 obesity drugs.
CEO highlights broader potential of 12-LOX inhibition beyond HIT; interested in partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.